Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 2
1969 2
1970 1
1971 1
1972 2
1974 1
1977 1
1978 1
1979 1
1980 1
1983 1
1984 2
1988 1
1989 3
1990 1
1992 2
1993 2
1994 1
1995 2
1997 6
1998 1
2000 3
2001 2
2002 3
2003 11
2004 15
2005 10
2006 13
2007 15
2008 12
2009 8
2010 17
2011 8
2012 2
2014 1
2015 2
2016 1
2017 1
2018 2
2019 5
2020 6
2021 2
2022 1
2023 3
2024 1
2025 5
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

169 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean pera g[au] (198 results)?
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.
Crown J, Stroyakovskii D, Yardley DA, Huang CS, Fasching PA, Bardia A, Chia S, Im SA, Martin M, Xu B, Barrios CH, Untch M, Moroose R, Hurvitz SA, Hortobagyi GN, Slamon DJ, Visco F, Spera G, Zarate JP, Halligan D, Li Z, Loi S. Crown J, et al. Among authors: spera g. ESMO Open. 2025 Nov;10(11):105858. doi: 10.1016/j.esmoop.2025.105858. Epub 2025 Oct 17. ESMO Open. 2025. PMID: 41320342 Free PMC article. Clinical Trial.
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.
Hurvitz SA, Martin M, Jung KH, Huang CS, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Fasching PA, Afenjar K, Spera G, Lopez-Valverde V, Song C, Trask P, Boulet T, Sparano JA, Symmans WF, Thompson AM, Slamon D. Hurvitz SA, et al. Among authors: spera g. J Clin Oncol. 2019 Sep 1;37(25):2206-2216. doi: 10.1200/JCO.19.00882. Epub 2019 Jun 3. J Clin Oncol. 2019. PMID: 31157583 Free PMC article. Clinical Trial.
PDGF and the testis.
Mariani S, Basciani S, Arizzi M, Spera G, Gnessi L. Mariani S, et al. Among authors: spera g. Trends Endocrinol Metab. 2002 Jan-Feb;13(1):11-7. doi: 10.1016/s1043-2760(01)00518-5. Trends Endocrinol Metab. 2002. PMID: 11750857 Review.
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
Hurvitz SA, Bardia A, Quiroga V, Park YH, Blancas I, Alonso-Romero JL, Vasiliev A, Adamchuk H, Salgado M, Yardley DA, Berzoy O, Zamora-Auñón P, Chan D, Spera G, Xue C, Ferreira E, Badovinac Crnjevic T, Pérez-Moreno PD, López-Valverde V, Steinseifer J, Fernando TM, Moore HM, Fasching PA; coopERA Breast Cancer study group. Hurvitz SA, et al. Among authors: spera g. Lancet Oncol. 2023 Sep;24(9):1029-1041. doi: 10.1016/S1470-2045(23)00268-1. Lancet Oncol. 2023. PMID: 37657462 Free article. Clinical Trial.
The Authors Respond.
Spera G, Fresco R, Fung H, Mackey JR. Spera G, et al. Epidemiology. 2018 Sep;29(5):e40. doi: 10.1097/EDE.0000000000000854. Epidemiology. 2018. PMID: 29771734 No abstract available.
Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials.
Blasco A, López-Tarruella S, Urruticoechea A, Carrasco E, Spera G, Martín M, Bermejo B, Chap L, Ruiz-Borrego M, Crown J, García-Saenz JA, Chan A, Guerrero-Zotano Á, Semiglazov V, Calvo L, Pienkowski T, Herranz J, Slamon D. Blasco A, et al. Among authors: spera g. Oncologist. 2025 Sep 1;30(9):oyaf263. doi: 10.1093/oncolo/oyaf263. Oncologist. 2025. PMID: 40838872 Free PMC article.
Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer.
Ferrario C, Mackey J, Gelmon KA, Levasseur N, Sorensen PH, Oo HZ, Negri GL, Tse VWL, Spencer SE, Cheng G, Morin GB, Del Rincon S, Cotechini T, Gonçalves C, Hindmarch CCT, Miller WH Jr, Amiri M, Basiri T, Villareal-Corpuz V, Sperry S, Gregorczyk K, Spera G, Sonenberg N, Pollak M. Ferrario C, et al. Among authors: spera g. Clin Cancer Res. 2025 Feb 3;31(3):491-502. doi: 10.1158/1078-0432.CCR-24-0841. Clin Cancer Res. 2025. PMID: 39576211 Clinical Trial.
Italian inter-societal manifesto for the prevention and therapy of sarcopenia: A way to raise awareness among institutions, the healthcare world and the population by: Ministry of Health, ADI (Italian Association of Dietetics and Clinical Nutrition), SIGG (Italian Society of Geriatrics and Gerontology), SIMFER (Italian Society of Physical and Rehabilitation Medicine), SINPE (Italian Society of Artificial Nutrition and Metabolism), SINU (Italian Society of Human Nutrition), SINuc (Italian Society of Clinical Nutrition and Metabolism), SIO (Italian Society of Obesity), SISA (Italian Society of Food Science), SISDCA (Italian Society for the study of Eating Disorders).
Copparoni R, Bagnato C, Barazzoni R, Beretta G, De Lorenzo A, Donini LM, Iolascon G, Landi F, Lezo A, Liguori N, Lucchin L, Migliaccio S, Muscaritoli M, Orlandoni P, Paolini B, Plutino G, Sorrento A, Spera G, Tagliabue A, Sara T, Zurlo V, Rondanelli M. Copparoni R, et al. Among authors: spera g. Clin Nutr ESPEN. 2025 Aug;68:248-253. doi: 10.1016/j.clnesp.2025.05.004. Epub 2025 May 7. Clin Nutr ESPEN. 2025. PMID: 40345655 Free article.
169 results